A potential regulatory loop between Lin28B:miR-212 in androgen-independent prostate cancer

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2421-2429

  Borrego Diaz, Emma ^a,b,c   Powers, Benjamin C ^a,b,c   Azizov, Vugar ^a,c   Lovell, Scott ^d   Reyes, Ruben ^a,b   Chapman, Bradley ^a   Tawfik, Ossama ^b,e   McGregor, Douglas ^c   Diaz, Francisco J ^a,b   Wang, Xinkun ^d   Van Veldhuizen, Peter ^a,b,c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF KANSAS   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen independent prostate cancer; C Myc downregulation; Lin28B silencing; Lin28B miR 212 c Myc pathway; Microrna regulation; MiR 212

Indexed keywords

ANDROGEN; LIN28B PROTEIN, HUMAN; MESSENGER RNA; MICRORNA; MYC PROTEIN; RNA BINDING PROTEIN;

ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 84907690309     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2647     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011.
2. Crawford ED, Stone NN, Yu EY, et al: Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology 83:664-669, 2014.
3. Trendel JA: The hurdle of antiandrogen drug resistance: drug design strategies. Expert Opin Drug Discov 8:1491-1501, 2013.
4. Mirnezami AH, Pickard K, Zhang L, Primrose JN and Packham G: MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol 35:339-347, 2009.
5. Ritchie W, Rasko JE and Flamant S: MicroRNA target prediction and validation. Adv Exp Med Biol 774:39-53, 2013.
6. Lovat F, Valeri N and Croce CM: MicroRNAs in the pathogenesis of cancer. Semin Oncol 38:724-733, 2011.
7. Hafner M, Max KE, Bandaru P, et al: Identification of mRNAs bound and regulated by human LIN28 proteins and molecular requirements for RNA recognition. RNA 19:613-626, 2013.
8. Zhou J, Ng SB and Chng WJ: LIN28/LIN28B: an emerging oncogenic driver in cancer stem cells. Int J Biochem Cell Biol 45:973-978, 2013.
9. Gaytan F, Sangiao-Alvarellos S, Manfredi-Lozano M, et al: Distinct expression patterns predict differential roles of the miRNA-binding proteins, Lin28 and Lin28b, in the mouse testis: studies during postnatal development and in a model of hypogonadotropic hypogonadism. Endocrinology 154:1321-1336, 2013.
10. Tummala R, Nadiminty N, Lou W, et al: Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol 183:288-295, 2013.
11. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) method. Methods 25:402-408, 2001.
12. Roy A, Kucukural A and Zhang Y: I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5:725-738, 2010.
13. Walter BA, Valera VA, Pinto PA and Merino MJ: Comprehensive microRNA profiling of prostate cancer. J Cancer 4:350-357, 2013.
14. Incoronato M, Urso L, Portela A, et al: Epigenetic regulation of miR-212 expression in lung cancer. PLoS One 6: e27722, 2011.
15. Xu B, Wang N, Wang X, et al: MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate 72:1171-1178, 2012.
16. Jones CI, Zabolotskaya MV, King AJ, et al: Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer 107:1987-1996, 2012.
17. Endo Y, Toyama T, Takahashi S, et al: miR-1290 and its potential targets are associated with characteristics of estrogen receptor alpha-positive breast cancer. Endocr Relat Cancer 20:91-102, 2013.
18. Sand M, Skrygan M, Sand D, et al: Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res 351:85-98, 2013.
19. Nurul-Syakima AM, Yoke-Kqueen C, Sabariah AR, Shiran MS, Singh A and Learn-Han L: Differential microRNA expression and identification of putative miRNA targets and pathways in head and neck cancers. Int J Mol Med 28:327-336, 2011.
20. Wang Z, Zhang H, Zhang P, Li J, Shan Z and Teng W: Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Med Oncol 30:577, 2013.
21. Xu K, Liang X, Cui D, Wu Y, Shi W and Liu J: miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drugsensitivity in human colorectal carcinoma cells. Mol Carcinog 52:70-78, 2013.
22. Hu H, Li S, Cui X, et al: The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). J Biol Chem 288:10973-10985, 2013.
23. An J, Pan Y, Yan Z, et al: MiR-23a in amplified 19p13.13 loci targets metallothionein 2A and promotes growth in gastric cancer cells. J Cell Biochem 114:2160-2169, 2013.
24. Li JH, Xiao X, Zhang YN, et al: MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecol Oncol 120:145-151, 2011.
25. Ferrajoli A, Shanafelt TD, Ivan C, et al: Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood 122:1891-1899, 2013.
26. Oh JS, Kim JJ, Byun JY and Kim IA: Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys 76:5-8, 2010.
27. Cui MH, Hou XL, Lei XY, et al: Upregulation of microRNA 181c expression in gastric cancer tissues and plasma. Asian Pac J Cancer Prev 14:3063-3066, 2013.
28. ∗ promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-κB/IκBα negative feedback loop. J Clin Invest 122:33-47, 2012.
29. Kashat M, Azzouz L, Sarkar SH, Kong D, Li Y and Sarkar FH: Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res 4:432-442, 2012.
30. Schaefer A, Jung M, Mollenkopf HJ, et al: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126:1166-1176, 2010.
31. Man YG, Fu SW, Liu AJ, et al: Aberrant expression of chromogranin A, miR-146a, and miR-146b-5p in prostate structures with focally disrupted basal cell layers: an early sign of invasion and hormone-refractory cancer? Cancer Genomics Proteomics 8:235-244, 2011.
32. Bray I, Tivnan A, Bryan K, et al: MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett 303:56-64, 2011.
33. Yang L, Li Y, Cheng M, et al: A functional polymorphism at microRNA-629-binding site in the 3'-untranslated region of NBS1 gene confers an increased risk of lung cancer in Southern and Eastern Chinese population. Carcinogenesis 33:338-347, 2012.
34. Ali PS, Ghoshdastider U, Hoffmann J, Brutschy B and Filipek S: Recognition of the let-7g miRNA precursor by human Lin28B. FEBS Lett 586:3986-3990, 2012.
35. Nam Y, Chen C, Gregory RI, Chou JJ and Sliz P: Molecular basis for interaction of let-7 microRNAs with Lin28. Cell 147:1080-1091, 2011.
36. Nadiminty N, Tummala R, Lou W, et al: MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One 7: e32832, 2012.
37. Vencio EF, Nelson AM, Cavanaugh C, et al: Reprogramming of prostate cancer-associated stromal cells to embryonic stem-like. Prostate 72:1453-1463, 2012.
38. Kong D, Banerjee S, Ahmad A, et al: Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 5: e12445, 2010.